secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001404644-24-000091
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurogene reports positive interim efficacy data from low-dose cohort of NGN-401 gene therapy for Rett syndrome
--------------------------------------------------------------------------------

- All 4 low-dose participants achieved a 2-point improvement on clinician-rated CGI-I scale from baseline.
- Caregiver-completed RSBQ scores improved 28–52% from baseline; participants acquired developmental milestones not seen in natural history.
- Low-dose NGN-401 well-tolerated with no treatment-related SAEs; emerging SAE noted in a third high-dose participant.
- Initiated adolescent/adult cohort (age ≥16) and gained FDA alignment on potency assay and manufacturing scale-up for registrational trial.
- Company discontinued CLN5 Batten disease program after RMAT application denial; evaluating options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000140464424000091/0001404644-24-000091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000140464424000091/ngne-20241111.htm
  HTML page:      https://secwatch.observer/filing/0001404644-24-000091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer